Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Combination Chemotherapy In Treating Patients With Advanced Cancer

This study has been completed.
Information provided by:
Barbara Ann Karmanos Cancer Institute Identifier:
First received: November 1, 1999
Last updated: April 5, 2013
Last verified: April 2013

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Phase I trial to study the effectiveness of combining gemcitabine, fluorouracil-uracil and leucovorin in treating patients who have advanced cancer that has not responded to previous therapy.

Condition Intervention Phase
Unspecified Adult Solid Tumor, Protocol Specific
Drug: gemcitabine hydrochloride
Drug: leucovorin calcium
Drug: tegafur-uracil
Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Phase I Study of Gemcitabine (Gemzar) and UFT/Leucovorin

Resource links provided by NLM:

Further study details as provided by Barbara Ann Karmanos Cancer Institute:

Estimated Enrollment: 36
Study Start Date: May 1998
Study Completion Date: August 2007
Primary Completion Date: August 2007 (Final data collection date for primary outcome measure)
Detailed Description:


  • Determine the maximum tolerated doses of gemcitabine, fluorouracil-uracil (UFT), and leucovorin calcium in patients with advanced refractory cancer.
  • Assess the toxicity of this combination regimen in this patient population.
  • Evaluate this regimen in terms of response rate, response duration, and overall survival in these patients.

OUTLINE: This is a dose escalation study of gemcitabine and fluorouracil-uracil.

Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15. Patients receive oral leucovorin calcium immediately followed by oral fluorouracil-uracil (UFT) three times a day on days 1-21. Courses are repeated every 28 days. Treatment continues in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of gemcitabine and UFT until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicities.

PROJECTED ACCRUAL: A total of 36 patients will be accrued for this study.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Histologically or cytologically confirmed malignancy refractory to existing chemotherapy or for which no standard therapy exists
  • Evaluable disease



  • 18 and over

Performance status:

  • SWOG 0-2

Life expectancy:

  • Greater than 3 months


  • Absolute neutrophil count greater than 1,500/mm3
  • Platelet count greater than 100,000/mm3
  • Hemoglobin greater than 8.0 mg/dL


  • Bilirubin less than 2.0 mg/dL
  • AST less than 3.0 times upper limit of normal


  • Creatinine no greater than 2.0 mg/dL


  • No active infection requiring antibiotics
  • Not pregnant or nursing
  • Fertile patients must use effective barrier contraception


Biologic therapy:

  • Not specified


  • At least 3 weeks since prior systemic cytotoxic chemotherapy (including fluorouracil) and recovered
  • No prior gemcitabine

Endocrine therapy:

  • Prior hormonal therapy allowed
  • No concurrent hormonal contraception


  • At least 3 weeks since prior radiotherapy to large areas of active bone marrow and recovered


  • Prior major surgery allowed and recovered


  • No prior or concurrent antiviral nucleosides
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00003925

United States, Michigan
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States, 48201-1379
Sponsors and Collaborators
Barbara Ann Karmanos Cancer Institute
Study Chair: Philip A. Philip, MD, PhD, FRCP Barbara Ann Karmanos Cancer Institute
  More Information

Additional Information:
Publications: Identifier: NCT00003925     History of Changes
Other Study ID Numbers: CDR0000067112, P30CA022453, WSU-D-1641, WSU-04-28-98-M02-FB, NCI-G99-1526
Study First Received: November 1, 1999
Last Updated: April 5, 2013
Health Authority: United States: Federal Government

Keywords provided by Barbara Ann Karmanos Cancer Institute:
unspecified adult solid tumor, protocol specific

Additional relevant MeSH terms:
Anti-Infective Agents
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Radiation-Sensitizing Agents
Therapeutic Uses processed this record on November 25, 2014